Skip to main content
SpringerLink
Log in

Leukotriene Receptor Antagonists in Virus-Induced Wheezing

Evidence to Date

  • Leading Article
  • Published:
Treatments in Respiratory Medicine

Abstract

Virus-induced wheezing is a relatively benign entity that is usually transient in early childhood but is responsible for much health care utilization. The condition, seen traditionally as a subset of those children diagnosed as having frequent episodic asthma, is often treated with inhaled corticosteroids, despite their lack of efficacy. However, there remains some confusion differentiating atopic asthma from virus-induced wheezing in young children and their respective treatment strategies.

The demonstration of cysteinyl leukotrienes in the nasopharyngeal secretions of infants and young children who wheeze prompted investigation of the role of leukotriene receptor antagonists in the treatment of virus-induced wheezing for young children with bronchiolitis and virus-induced wheezing.

Montelukast, the only leukotriene receptor antagonist studied in young children, has been proven useful in increasing the number of symptom-free days and delaying the recurrence of wheeze in the month following a diagnosis of respiratory syncytial virus-induced wheezing in children aged 3–36 months. Subsequently, in children aged 2–5 years with frequent episodic asthma, primarily involving viral induced attacks in this age group, regular therapy with daily montelukast for 12 months reduced the rate of asthma exacerbations by 31% over placebo, delayed the time to the first exacerbation by 2 months, and lowered the need to prescribe inhaled corticosteroids as preventative therapy. Additionally, montelukast has been demonstrated to be efficacious as an acute episode modifier in children aged 2–14 years (85% children <6 years) with virus-induced wheezing where it was prescribed at the onset of a viral infection in children with an established pattern of viral induced episodes of wheeze in the preceding year. In this study, emergency department visits were reduced by 45%, visits to all health care practitioners were reduced by 23%, and time of preschool/school and parental time off work was reduced by 33% for children who took montelukast for a median of 10 days.

At present, there is good evidence to support the use of bronchodilators in the acute treatment of virus-induced wheezing, and increasing evidence to support the use of leukotriene receptor antagonists, in particular montelukast, in the management of children with virus-induced wheezing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Martinez FD, Wright AL, Taussig LM, et al. Asthma and wheezing in the first six years of life. N Engl J Med 1995; 332: 133–8

    Article  PubMed  CAS  Google Scholar 

  2. Taussig LM, Wright L, Holberg CJ, et al. Tucson children’s respiratory study: 1980 to present. J Allergy Clin Immunol 2003; 111: 661–75

    Article  PubMed  Google Scholar 

  3. Martinez FD, Morgan WJ, Wright AL, et al. Diminished lung function as a predisposing factor for wheezing respiratory illness in infants. N Engl J Med 1988; 319(17): 1112–7

    Article  PubMed  CAS  Google Scholar 

  4. Turner SW, Palmer LJ, Rye PJ, et al. The relationship between infant airway function, childhood airway responsiveness, and asthma. Am J Respir Crit Care Med 2004; 169: 921–7

    Article  PubMed  Google Scholar 

  5. Tager IB, Hanrahan JP, Tostesan TD, et al. The natural history of respiratory symptoms in preschool children. Am J Respir Crit Care Med 1995; 152: 1872–8

    Google Scholar 

  6. Lau S, Sommerfeld C, Niggemann B, et al. Transient early wheeze is not associated with impaired lung function in 7 year old children. Eur Respir J 2003; 21: 834–41

    Article  PubMed  CAS  Google Scholar 

  7. Stevenson EC, Turner G, Heaney LG, et al. Bronchoalveolar lavage findings suggest two different forms of childhood asthma. Clin Exp Allergy 1997; 27: 1027–35

    Article  PubMed  CAS  Google Scholar 

  8. Silverman M. Out of the mouths of babes and sucklings: lessons from early childhood asthma. Thorax 1993; 49: 1200–4

    Article  Google Scholar 

  9. Hogg C, Bush A. Childhood asthma: all that wheezes is not inflammation. Clin Exp Allergy 1997; 27: 991–4

    Article  PubMed  CAS  Google Scholar 

  10. Wilson N, Sloper K, Silverman M. Effect of continuous treatment with topical corticosteroid on episodic viral wheeze in preschool children. Arch Dis Child 1995; 72: 317–20

    Article  PubMed  CAS  Google Scholar 

  11. Stick SM, Burton PR, Clough JB, et al. The effects of inhaled beclomethasone dipropionate on lung function and histamine responsiveness in recurrently wheezy infants. Arch Dis Child 1995; 73: 327–32

    Article  PubMed  CAS  Google Scholar 

  12. Oommen A, Lambert PC, Grigg J. Efficacy of a short course of parent initiated oral prednisolone for viral wheeze in children aged 1–5 years: randomised controlled trial. Lancet 2003; 362: 1433–8

    Article  PubMed  CAS  Google Scholar 

  13. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children. J Am Med Assoc 1998; 279: 1181–6

    Article  CAS  Google Scholar 

  14. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108(3): e48

    Article  PubMed  CAS  Google Scholar 

  15. Bisgaard H, Zielen S, Garcia-Garcia ML, et al. Montelukast reduces asthma exacerbations in 2-5 year old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171: 315–22

    Article  PubMed  Google Scholar 

  16. Robertson CF, Henry RL, Mellis CM, et al. Short course montelukast for intermittent asthma in children: the PRE-EMPT study [abstract]. Am J Respir Crit Care Med 2004; 169: A149

    Google Scholar 

  17. Stein RT, Holberg CJ, Morgan WJ, et al. Peak flow variability, methacholine responsiveness and atopy as markers for detecting different wheezing phenotypes in childhood. Thorax 1997; 52: 946–52

    Article  PubMed  CAS  Google Scholar 

  18. Young S, Arnott J, O’Keeffe PT, et al. The association between early life lung function and wheezing during the first 2 years of life. Eur Respir J 2000; 15: 151–7

    Article  PubMed  CAS  Google Scholar 

  19. Martinez FD, Wright AL, Holberg CJ, et al. Maternal age as a risk factor for wheezing lower respiratory illnesses in the first year of life. Am J Epidemiol 1992 Nov 15; 136: 1258–68

    PubMed  CAS  Google Scholar 

  20. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999; 353: 541–5

    Article  Google Scholar 

  21. Dezateux C, Fletcher ME, Dundas I, et al. Infant respiratory function after RSV-proven bronchiolitis. Am J Respir Crit Care Med 1997; 155: 1349–55

    PubMed  CAS  Google Scholar 

  22. Sporik R, Holgate ST, Cogswell JJ. Natural history of asthma in childhood: a birth cohort study. Arch Dis Child 1991; 66: 1050–3

    Article  PubMed  CAS  Google Scholar 

  23. Van Asperen PP, Mukhi A. Role of atopy in the natural history of wheeze and bronchial hyper-responsiveness in childhood. Pediatr Allergy Immunol 1994; 5: 178–83

    Article  PubMed  Google Scholar 

  24. Asthma Management Handbook. 5th ed. Melbourne, Australia: National Asthma Council, 2002

  25. Kurukulaaratchy RJ, Fenn MH, Waterhouse LM, et al. Characterization of wheezing phenotypes in the first 10 years of life. Clin Exp Allergy 2003 May; 33(5): 573–8

    Article  PubMed  CAS  Google Scholar 

  26. Balfour-Lynn IM. Why do viruses make infants wheeze? Arch Dis Child 1996; 74: 251–9

    Article  PubMed  CAS  Google Scholar 

  27. Wright AL, Taussig LM, Ray CG, et al. The Tucson Children’s Respiratory Study: II. lower respiratory tract illness in the first year of life. Am J Epidemiol 1989; 129: 1232–46

    CAS  Google Scholar 

  28. Pattemore PK, Johnston SL, Bardin PG. Viruses as precipitants of asthma symptoms: I. epidemiology. Clin Exp Allergy 1992; 22: 325–36

    Article  CAS  Google Scholar 

  29. Doull IJ. Limitations of maintenance therapy for viral respiratory infection-induced asthma. J Pediatr 2003; 142(2 Suppl.): S21–4

    Article  PubMed  Google Scholar 

  30. Bardin PG, Johnston SL, Pattemore PK. Viruses as precipitants of asthma symptoms: II. physiology and mechanisms. Clin Exp Allergy 1992; 22: 809–22

    Article  CAS  Google Scholar 

  31. Empey DW, Laitinen LA, Jacobs L, et al. Mechanisms of bronchial hyperreactivity in normal subjects after upper respiratory tract infection. Am Rev Respir Dis 1976; 113: 131–9

    PubMed  CAS  Google Scholar 

  32. Cuss FM, Barnes PJ. Airway smooth muscle and disease workshop: epithelial mediators. Am Rev Respir Dis 1987; 136: S32–5

    PubMed  CAS  Google Scholar 

  33. Barbato A, Turato G, Baraldo S, et al. Airway inflammation in childhood asthma. Am J Respir Crit Care Med 2003; 168: 798–803

    Article  PubMed  Google Scholar 

  34. Volovitz B, Faden H, Ogra PL. Release of leukotriene C4 in the respiratory tract during acute viral infection. J Pediatr 1988; 112: 218–22

    Article  PubMed  CAS  Google Scholar 

  35. Volvovitz B, Welliver RC, De Castro G, et al. The release of leukotrienes in the respiratory tract during infection with respiratory syncytial virus: role in obstructive airway disease. Pediatr Res 1988; 24: 504–7

    Article  Google Scholar 

  36. Balfour-Lynn IM, Valman HB, Wellings R, et al. Tumour necrosis factor-alpha and leukotriene E4 production in wheezy infants. Clin Exp Allergy 1994; 24: 121–6

    Article  PubMed  CAS  Google Scholar 

  37. Oommen A, Grigg J. Urinary leukotriene E4 in preschool children with acute clinical viral wheeze. Eur Respir J 2003; 21: 149–54

    Article  PubMed  CAS  Google Scholar 

  38. Stevenson EC, Turner G, Heaney LG, et al. Bronchoalveolar lavage findings suggest two different forms of childhood asthma. Clin Exp Allergy 1997; 27(9): 1027–35

    Article  PubMed  CAS  Google Scholar 

  39. Sampson AP, Castling DP, Green CP, et al. Persistent increase in plasma and urinary leukotrienes after acute asthma. Arch Dis Child 1995; 73: 221–5

    Article  PubMed  CAS  Google Scholar 

  40. Martinez FD, Stern DA, Wright AL, et al. Differential immune responses to acute lower respiratory illness in early life and subsequent development of persistent wheezing and asthma. J Allergy Clin Immunol 1998; 102: 915–20

    Article  PubMed  CAS  Google Scholar 

  41. Gibson PG, Simpson JL, Chalmers AC, et al. Airway eosinophilia is associated with wheeze but is uncommon in children with persistent cough and frequent chest colds. Am J Respir Crit Care Med 2001; 164: 977–81

    PubMed  CAS  Google Scholar 

  42. Clough JB, Holgate ST. Episodes of respiratory morbidity in children with cough and wheeze. Am J Respir Crit Care Med 1994; 150: 48–53

    PubMed  CAS  Google Scholar 

  43. Wright AL, Holberg CJ, Morgan WJ, et al. Recurrent cough in childhood and its relation to asthma. Am J Respir Crit Care Med 1996; 153: 1259–65

    PubMed  CAS  Google Scholar 

  44. Brooke AM, Lambert PC, Burton PR, et al. Recurrent cough, natural history and significance in infancy and early childhood. Pediatr Pulmonol 1998; 26: 256–61

    Article  PubMed  CAS  Google Scholar 

  45. Straub DA, Moeller A, Minocchieri S, et al. The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma. Eur Respir J 2005; 25: 289–93

    Article  PubMed  CAS  Google Scholar 

  46. Murphy RC, Hammarstrom S, Samuelsson B. Leukotriene C, a slow reacting substance [SRS] from mouse mastrocytoma cells. Proc Natl Acad Sci U S A 1979; 76: 4275–9

    Article  PubMed  CAS  Google Scholar 

  47. Brocklehurst WE. The release of histamine and formation of a slow reacting substance [SRS-A] during anaphylactic shock. J Physiol 1960; 151: 416–35

    PubMed  CAS  Google Scholar 

  48. Spahr JE, Krawiec ME. Leukotriene receptor antagonists: risks and benefits for use in paediatric asthma. Expert Opin Drug Saf 2004; 3: 173–85

    Article  PubMed  CAS  Google Scholar 

  49. Horwitz RJ, McGill KA, Busse WW. The role of leukotriene modifiers in the treatment of asthma. Am J Respir Crit Care Med 1998; 157: 1363–71

    PubMed  CAS  Google Scholar 

  50. Samuelsson B, Dahlen SE, Lindgren JA, et al. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237: 1171–6

    Article  PubMed  CAS  Google Scholar 

  51. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990; 323: 645–55

    Article  PubMed  CAS  Google Scholar 

  52. Penrose JF, Spector J, Lam BK, et al. LTC4 synthase at nuclear membrane. Am J Respir Crit Care Med 1995; 152: 283–9

    PubMed  CAS  Google Scholar 

  53. Gibson PG, Norzila MZ, Fakes K, et al. Pattern of airway inflammation and its determinants in children with acute severe asthma. Pediatr Pulmonol 1999 Oct; 28(4): 261–70

    Article  PubMed  CAS  Google Scholar 

  54. Gibson PG, Allen CJ, Yang JP, et al. Intraepithelial mast cells in allergic and nonallergic asthma: assessment using bronchial brushings. Am Rev Respir Dis 1993 Jul; 148(1): 80–6

    PubMed  CAS  Google Scholar 

  55. Teran LM, Johnston SL, Schroder JM, et al. Role of nasal interleukin-8 in neutrophil recruitment and activation in children with virus-induced asthma. Am J Respir Crit Care Med 1997 Apr; 155(4): 1362–6

    PubMed  CAS  Google Scholar 

  56. Johnston SL, Pattemore PK, Sanderson G, et al. The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med 1996 Sep; 154 (3 Pt 1): 654–60

    PubMed  CAS  Google Scholar 

  57. Keatings VM, Jatakanon A, Worsdell YM, et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997 Feb; 155(2): 542–8

    PubMed  CAS  Google Scholar 

  58. Taylor GW, Black P, Turner N. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989; I: 584–8

    Article  Google Scholar 

  59. Severien C, Artlich A, Jonas G, et al. Urinary excretion of leukotriene E4 and eosinophil protein X in children with atopic asthma. Eur Respir J 2000; 16: 588–92

    Article  PubMed  CAS  Google Scholar 

  60. Westcott JY, Smith HR, Wenzel SE, et al. Urinary leukotrieneE4 in patients with asthma: effect of airways reactivity and sodium cromoglycate. Am Rev Respir Dis 1991; 143: 1322–8

    PubMed  CAS  Google Scholar 

  61. Christie PE, Tagari P, Ford Hutchinson AW, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991; 143: 1025–9

    PubMed  CAS  Google Scholar 

  62. Manning PJ, Rokach J, Malo JL, et al. Urinary leukotriene E4 levels during early and late asthmatic responses. J Allergy Clin Immunol 1990; 86: 211–20

    Article  PubMed  CAS  Google Scholar 

  63. Drazen JM, Austen KF, Lewis RA, et al. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci U S A 1980; 77: 4354–8

    Article  PubMed  CAS  Google Scholar 

  64. Dahlen SE, Hedqvist P, Hammarstrom S, et al. Leukotrienes are potent constrictors of human bronchi. Nature 1980; 288: 484–6

    Article  PubMed  CAS  Google Scholar 

  65. Laitinen LA, Laitinen A, Haahtela T, et al. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 1993; 341: 989–90

    Article  PubMed  CAS  Google Scholar 

  66. Shimuzu T, Hirano H, Majima Y, et al. A mechanism of antigen induced mucus production in nasal epithelium of sensitized rats: a comparison with lipopolysaccharide-induced mucus production. Am J Respir Crit Care Med 2000; 161: 1648–54

    Google Scholar 

  67. Barnes NC, Piper PJ, Costello JF. Comparative actions of inhaled leukotriene C4, leukotriene D4 and histamine in normal human subjects. Thorax 1984; 39: 500–4

    Article  PubMed  CAS  Google Scholar 

  68. Adelroth E, Morris MM, Hargreave FE. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. N Engl J Med 1986; 315: 480–4

    Article  PubMed  CAS  Google Scholar 

  69. Marom Z, Shelhamer JH, Bach MK, et al. Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982; 126: 449–51

    PubMed  CAS  Google Scholar 

  70. Diamant Z, Hiltermann JT, van Rensen EL, et al. The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma. Am Rev Respir Crit Care Med 1997; 155: 1247–53

    CAS  Google Scholar 

  71. Lynch KR, O’Neill GP, Liu Q, et al. Characterisation of the human cysteinyl leukotriene cys-LT1 receptor. Nature 1999; 399: 789–93

    Article  PubMed  CAS  Google Scholar 

  72. Heise CE, O’Dowd BF, Figueroa DJ, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000; 275: 30531–16

    Article  PubMed  CAS  Google Scholar 

  73. O’Connell EJ. Optimizing inhaled corticosteroid therapy in children with chronic asthma. Pediatr Pulmonol 2005; 39: 74–83

    Article  PubMed  Google Scholar 

  74. Powell H, Gibson PG. High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children. Cochrane Database Syst Rev 2004; (2): CD004109

  75. Randall T, Cowell C, Ambler G, et al. Safety of newer inhaled corticosteroids in asthma. Pediatr Drugs 2003; 5: 481–504

    Google Scholar 

  76. Sigurs N, Bjarnason R, Sigurbergsson F, et al. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000; 161: 1501–7

    PubMed  CAS  Google Scholar 

  77. Sigurs N. Epidemiologic and clinical evidence of a respiratory syncytial virus-reactive airways link. Am J Respir Crit Care Med 2001; 163: S2–6

    PubMed  CAS  Google Scholar 

  78. Fitzgerald DA, Kilham HA. Bronchiolitis: assessment and evidence based management. Med J Aust 2004; 180: 399–404

    PubMed  Google Scholar 

  79. Bisgaard H. A randomized controlled trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med 2003; 167: 379–83

    Article  PubMed  Google Scholar 

  80. Kellner JD, Ohlsson A, Gadomski AM, et al. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev 2000; (2): CD001266

  81. Roosevelt G, Sheehan K, Grupp-Phelan J, et al. Dexamethasone in bronchiolitis: a randomised controlled trial. Lancet 1996; 348: 292–5

    Article  PubMed  CAS  Google Scholar 

  82. Klassen TP, Sutcliffe T, Watters LK, et al. Dexamethasone in salbutamol treated inpatients with acute bronchiolitis: a randomised, controlled trial. J Pediatr 1997; 130: 191–6

    Article  PubMed  CAS  Google Scholar 

  83. Bulow SM, Nir M, Levin E, et al. Prednisolone treatment of respiratory syncytial virus infection: a randomized controlled trial of 147 infants. Pediatrics 1999; 104: e77

    Article  PubMed  CAS  Google Scholar 

  84. Richter H, Seddon P. Early nebulized budesonide in the treatment of bronchiolitis and the prevention of postbronchiolitic wheezing. J Pediatr 1998; 132: 849–53

    Article  PubMed  CAS  Google Scholar 

  85. Cade A, Brownlee KG, Conway SP, et al. Randomised placebo controlled trial of nebulized corticosteroids in acute respiratory syncytial viral bronchiolitis. Arch Dis Child 2000; 82: 126–30

    Article  PubMed  CAS  Google Scholar 

  86. Silverman M, Wilson N. Wheezing phenotypes in childhood. Thorax 1997; 52: 936–7

    Article  PubMed  CAS  Google Scholar 

  87. Webb MS, Henry RL, Milner AD. Oral corticosteroids for wheezing attacks under 18 months. Arch Dis Child 1986; 61: 15–9

    Article  PubMed  CAS  Google Scholar 

  88. Fox GF, Marsh MJ, Milner AD. Treatment of recurrent wheezing episodes in infancy with oral salbutamol and prednisolone. Eur J Pediatr 1996; 155: 512–6

    Article  PubMed  CAS  Google Scholar 

  89. Brunette MG, Lands L, Thibodeau LP. Childhood asthma: prevention of attacks with short-term corticosteroid treatment of upper respiratory tract infection. Pediatrics 1988; 81: 624–9

    PubMed  CAS  Google Scholar 

  90. McKean M, Ducharme F. Inhaled steroids for episodic viral wheeze of childhood. Cochrane Database Syst Rev 2000; (1): CD001107

  91. Wilson NM, Silverman M. Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroids at home. Arch Dis Child 1990; 65: 407–10

    Article  PubMed  CAS  Google Scholar 

  92. Duoll IJ, Lampe FC, Smith S, et al. Effect of inhaled corticosteroids on episodes of wheezing associated with viral infection in school age children: randomised double blind placebo controlled trial. BMJ 1997; 315: 858–62

    Article  Google Scholar 

  93. Connett G, Warde C, Wooler E, et al. Use of budesonide in severe asthmatics 1–3 years. Arch Dis Child 1993; 69: 351–5

    Article  PubMed  CAS  Google Scholar 

  94. Svedmyr J, Nyberg E, Thunqvist P, et al. Prophylactic intermittent treatment with inhaled corticosteroids of asthma exacerbations due to airway infection in toddlers. Acta Paediatr 1999; 88: 42–7

    Article  PubMed  CAS  Google Scholar 

  95. Wilson N, Sloper K, Silverman M. Effect of continuous treatment with topical corticosteroid on episodic viral wheeze in preschool children. Arch Dis Child 1995; 72: 317–20

    Article  PubMed  CAS  Google Scholar 

  96. Furfaro S, Spier S, Drbik SP, et al. Efficacy of cromoglycate in persistently wheezing infants. Arch Dis Child 1994; 71: 331–4

    Article  PubMed  CAS  Google Scholar 

  97. Tasche MJA, var der Wouden JC, Uijen JHJM, et al. Randomised placebo-controlled trial of inhaled sodium cromoglycate in 1–4 year old children with moderate asthma. Lancet 1997; 350: 1060–4

    Article  PubMed  CAS  Google Scholar 

  98. Roorda RJ, Mezei G, Bisgaard H, et al. Response of preschool children with asthma symptoms to fluticasone propionate. J Allergy Clin Immunol 2001; 108: 540–6

    Article  PubMed  CAS  Google Scholar 

  99. Bisgaard H, Allen D, Milanowski J, et al. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. Pediatrics 2004; 113: e87–94

    Article  PubMed  Google Scholar 

  100. Godden DJ, Ross S, Abdalla M, et al. Outcome of wheeze in childhood: symptoms and pulmonary function 25 years later. Am J Respir Crit Care Med 1994; 149: 106–12

    PubMed  CAS  Google Scholar 

  101. Ducharme FM, di Salvio F. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in children. Cochrane Database Syst Rev 2004; (1): CD002314

  102. Van Asperen PP, Mellis CM, Sly PD. The role of corticosteroids in the management of childhood asthma. Med J Aust 2002; 176: 168–73

    Google Scholar 

  103. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115: 233–42

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

DF and CM are members of the Singulair (montelukast) Medical Advisory Board to MSD Australia for which they receive an honorarium. They have participated in Australian and multinational clinical trials involving montelukast. Both DF and CM have received honoraria for lectures given and attended educational medical meetings sponsored by GlaxoSmithKline, AstraZeneca, and Merck Sharpe & Dohme in the last 5 years. No sources of funding were used to assist in the preparation of this article.

Author information

Authors and Affiliations

  1. Department of Respiratory Medicine, The Children’s Hospital at Westmead, Locked Bag 4001, Westmead, Sydney, New South Wales, 2145, Australia

    Dominic A. Fitzgerald

  2. Discipline of Paediatrics and Child Health, Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia

    Dominic A. Fitzgerald

  3. Central Clinical School, Faculty of Medicine, University of Sydney, Sydney, New South Wales, Australia

    Craig M. Mellis

Authors
  1. Dominic A. Fitzgerald
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Craig M. Mellis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dominic A. Fitzgerald.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fitzgerald, D.A., Mellis, C.M. Leukotriene Receptor Antagonists in Virus-Induced Wheezing. Treat Respir Med 5, 407–417 (2006). https://doi.org/10.2165/00151829-200605060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151829-200605060-00006

Keywords

Search

Navigation